Fox, my apologies for the late response; the more so because I was so eagerly awaiting your posts.
"Can you or anyone post:
- is there a new IR person;
- does that mean that Renny Ho is gone?
- if yes to either, does anyone have an email address?"
The best summary I've seen of the CC was by Cal Gary, here:
Message 18468410
As far as I know, Rennie Ho is still with DMX.
Hope that helps.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
WRT your research in Thailand, excellent! I realize that its a slog, and I'm sure everyone appreciates the effort.
"...there has been a test under way in Canada for the past 2 years, under the SAP program of HC. I can find absolutely zilch, about it, on the HC SAP site. Am I the only one who was unaware of this?"
Fox, I think a lot of people were unaware of this; I know I was. I don't know of anyone besides Greg Pugen that is treating people with WF10, so I assume that the SAP data relates to his patients. It doesn't appear to be a "trial" in the accepted sense, but rather a collection of data on his patients, whose treatments have been for a wide range of conditions.
The Thai info was somewhat disappointing, in that it was so limited. I never got any further response from the mystery SH poster, "supposedly" using WF10 off-label in Thailand. We'll have to chalk it up as bogus, I guess.
"There have been safety studies completed here, but the main one is yet to be announced. It is referenced as <the WF10-98-THAI-01CYS study>."
I suspect the study will confirm what we already know: the safety of WF10 is well-established.
The story is that Oxo Chemie and DMX have sought to keep WF10 "under wraps" - until the time is right. Judging by the CC, the right time is fast approaching.
Given all the difficulty that DMX has had with the P3 data, I simply don't believe they would have struggled this far, if the data was equivocal. I recognize the legitimate warnings to be cautious - but I believe efficacy is established. The question was in the acceptability of the data. The fact that DMX has struggled to get the data to the FDA - and is in the process of doing so - makes me believe we have a winner.
Why? Because if the data was doubtful, I think DMX would simply have dropped the matter - as many others have done, with inconclusive P3 data.
That's just an inference, an opinion: time will tell.
Thanks again for your efforts.
Jim |
